Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 12
Submit an article Journal homepage
607
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma

Hongfu CaiDepartment of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China; View further author information
,
Longfeng ZhangDepartment of Medical Oncology, Fujian Provincial Cancer Hospital, Fuzhou, ChinaView further author information
,
Na LiDepartment of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China; View further author information
,
Bin ZhengDepartment of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China; View further author information
&
Maobai LiuDepartment of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China; Correspondence[email protected]
View further author information
Pages 2951-2959 | Received 20 Feb 2019, Accepted 06 May 2019, Published online: 04 Jun 2019

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Mimi Choon-Quinones, Tamás Zelei, Bertalan Németh, Manna Tóth, Xiao Yang Jia, Mike Barnett, Paul Keown, Brian Durie, Jean-Luc Harousseau, Dirk Hose & Zoltán Kaló. (2023) Systematic literature review of health economic models developed for multiple myeloma to support future analyses. Journal of Medical Economics 26:1, pages 110-119.
Read now

Articles from other publishers (8)

Zixuan He, Xianqin Huang, Dingyi Chen, Guoan Wang, Yuezhen Zhu, Huangqianyu Li, Sheng Han, Luwen Shi & Xiaodong Guan. (2023) Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review. BMJ Global Health 8:11, pages e012780.
Crossref
Lineo Marie Matsela, Susan Cleary & Thomas Wilkinson. (2022) Cost utility and budget impact analysis of dexamethasone compared with bortezomib and lenalidomide for the treatment of second line multiple myeloma from a South African public health perspective. Cost Effectiveness and Resource Allocation 20:1.
Crossref
Liu Liu, Zhixin Jiang, Fuming Li, Yan Wei, Jian Ming, Yi Yang, Shimeng Liu, Lizheng Shi & Yingyao Chen. (2022) Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list. BMC Health Services Research 22:1.
Crossref
Maarten R. Seefat, David G. J. Cucchi, Stijn Dirven, Kaz Groen, Sonja Zweegman & Hedwig M. Blommestein. (2021) A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma. Cancers 13:22, pages 5606.
Crossref
Xiaohui Zeng, Qiao Liu, Liubao Peng, Ye Peng, Lidan Yi, Xia Luo, Sini Li, Xiaomin Wan & Chongqing Tan. (2021) Cost-Effectiveness Analysis of Adding Daratumumab to a Regimen of Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma. Advances in Therapy 38:5, pages 2379-2390.
Crossref
Yujia Zhai, Dai Yuan, Xueling Ge, Shunfeng Hu, Peipei Li, Xiaosheng Fang, Ying Li, Xiangxiang Zhou & Xin Wang. (2021) Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety. Frontiers in Oncology 11.
Crossref
Longfeng Zhang, Xiaofang Zeng, Hongfu Cai, Na Li, Maobai Liu, Lingling Qiu & Bin Zheng. (2020) Cost–effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer. Journal of Comparative Effectiveness Research 9:18, pages 1301-1309.
Crossref
Hongfu Cai, Longfeng Zhang, Na Li, Bin Zheng & Maobai Liu. (2020) Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis. Journal of Comparative Effectiveness Research 9:8, pages 553-562.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.